Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC

SummaryThe aim of the study was to analyze the relation between tumor volume (Vpath), tumor marker index (TMI) and prognosis in 261 completely resected (R0) stages I and II non-small cell lung cancer (NSCLC) patients by univariate and multivariate analyses. Vpath was calculated as an ellipsoid body. TMI represents the geometric mean of normalized CYFRA 21-1 and CEA values. Patients with a Vpath ≤ 13.7 cm3 had a significantly better 5-year-survival rate than patients with a Vpath > 13.7 cm3 (78.1% vs. 47.9%; p < 0.001). Patients with a TMI ≤ 0.54 had a 5-year-survival rate of 79.1% compared to only 47.2% in patients with a TMI > 0.54 (p < 0.001). Besides age (>70 years), performance status and gender, both Vpath (>13.7 cm3) and TMI (>0.54) bore significance in the multivariate Cox model with a hazard ratio (HR) of 1.9 (95% CI: 1.1–3.3, p = 0.016) and 2.3 (95% CI: 1.3–4.2, p = 0.006), respectively. Based on a combination of Vpath and TMI, a low risk group (17% of the patients) with both parameters in the normal range could be identified. Patients with elevated Vpath or TMI (31%) had an intermediate HR of 3.4 (95% CI: 1.3–9.2). When both factors were elevated (52% of patients) the HR increased to 5.95 (95% CI: 2.4–14.9). The elevation of Vpath and TMI was found in 46.2% of stage I and in 59.1% of stage II. The 5-year-survival rates were found to be 89.1, 62.2 and 43.0%, respectively. In conclusion, elevated levels of TMI and Vpath have a strong negative prognostic impact on survival in operated early stage of NSCLC. These patients might be considered for adjuvant chemotherapy.